Gilead Sciences files 13F listing $1.94B in holdings

Q: How many holdings and what total value are reported for Gilead (GILD)?

The filing reports 6 holdings with a combined value of $1,935,507,854. This figure is the Form 13F Information Table Value Total, rounded to the nearest dollar, as shown on the report summary.

Q: Who signed Gilead's Form 13F and what is their title?

The Form 13F was signed by Andrew D. Dickinson, whose title is Executive Vice President and Chief Financial Officer. The signature block lists his telephone number and the signing location as Foster City, California.

Q: Is this filing a full 13F Holdings Report or a notice/combination?

This submission is marked as a 13F HOLDINGS REPORT, indicating that all holdings of this reporting manager are reported in this report, as checked on the Report Type line of the cover page.

Gilead Sciences filed a Form 13F Holdings Report disclosing its institutional holdings.

Accepted by SEC EDGAR 02/12/2026 - 04:36 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

13F-HR

Rhea-AI Filing Summary

Gilead Sciences filed a Form 13F Holdings Report disclosing its institutional holdings. The filing lists 6 reported holdings with a combined market value of $1,935,507,854. The report was signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, on 02-12-2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does GILD's Form 13F filed on 02-12-2026 disclose?

The Form 13F discloses institutional holdings as a 13F Holdings Report. It lists 6 holdings totaling $1,935,507,854 in market value, and the filing was signed by Andrew D. Dickinson on 02-12-2026.

How many holdings and what total value are reported for Gilead (GILD)?

The filing reports 6 holdings with a combined value of $1,935,507,854. This figure is the Form 13F Information Table Value Total, rounded to the nearest dollar, as shown on the report summary.

Who signed Gilead's Form 13F and what is their title?

The Form 13F was signed by Andrew D. Dickinson, whose title is Executive Vice President and Chief Financial Officer. The signature block lists his telephone number and the signing location as Foster City, California.

Does Gilead's 13F include other included managers?

Yes; the report summary lists 1 other included manager. The List of Other Included Managers names Gilead Therapeutics A1 Unlimited Co with Form 13F File No. 028-25083.

Is this filing a full 13F Holdings Report or a notice/combination?

This submission is marked as a 13F HOLDINGS REPORT, indicating that all holdings of this reporting manager are reported in this report, as checked on the Report Type line of the cover page.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL

OMB Number:			3235-0006
Estimated average burden
hours per response:			23.8

Report for the Calendar Year or Quarter Ended:

12-31-2025

Check here if Amendment		Amendment Number:
This Amendment (Check only one.):		is a restatement.
		adds new holdings entries.

Institutional Investment Manager Filing this Report:
Name:	GILEAD SCIENCES, INC.
Address:	333 LAKESIDE DR

	FOSTER CITY, CA 94404
Form 13F File Number:	028-25078
CRD Number (if applicable):
SEC File Number (if applicable):

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name:	Andrew D. Dickinson
Title:	Executive Vice President and Chief Financial Officer
Phone:	650-574-3000
Signature, Place, and Date of Signing:
/s/ Andrew D. Dickinson		FOSTER CITY, CA	02-12-2026
[Signature]		[City, State]	[Date]

Report Type (Check only one.):
X	13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
	13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
	13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page
	Report Summary:
	Number of Other Included Managers:	1
	Form 13F Information Table Entry Total:	6
	Form 13F Information Table Value Total:	1,935,507,854
		(round to nearest dollar)

List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]
	No.	Name	Form 13F File No.	CRD No. (if applicable)	SEC File No. (if applicable)	CIK
	1	Gilead Therapeutics A1 Unlimited Co	028-25083			0002055207

Source: View Original Filing on SEC EDGAR